Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
The purpose of this study was to evaluate response rates, 1st remission duration (FRD), and toxicity in dogs with previously untreated lymphoma receiving an identical CHOP-based combination chemotherapy protocol with or without L-asparaginase (LASP). One hundred fifteen dogs with lymphoma were scheduled to receive an identical CHOP-based chemotherapy protocol that included L-ASP. However, because of manufacturer-imposed random rationing, 31 dogs did not receive L-ASP as scheduled. The 2 treatment groups were statistically similar with respect to signalment and presence of historical negative prognostic factors. No difference was observed in the median FRD whether dogs did or did not receive L-ASP (206 versus 217 days, respectively; P = .67). No difference was observed in the median overall survival times between dogs receiving or not receiving L-ASP (310 versus 308 days, respectively; P = .84). No statistical difference was observed with respect to overall response rate between dogs that did or did not receive L-ASP (89.3% versus 87.1%, respectively; P = .75). Complete response rates between the groups also were no different (83.3% and 77.4% for L-ASP and non-L-ASP groups, respectively; P = .59). Prevalence of toxicity (neutropenia, diarrhea, or vomiting) and treatment delays (P = .80) also were similar between groups. The results of this study suggest that exclusion of L-ASP in this multidrug protocol does not significantly impact outcome. Therefore, it may be more appropriate to reserve the use of L-ASP for treating relapse in dogs with lymphoma that have failed induction therapy.
MacDonald
Valerie S
VS
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Thamm
Douglas H
DH
Kurzman
Ilene D
ID
Turek
Michelle M
MM
Vail
David M
DM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001215:Asparaginase / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000662:veterinary; D001774:Blood Chemical Analysis / Q000662:veterinary; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D012074:Remission Induction; D016019:Survival Analysis; D016482:Urinalysis / Q000662:veterinary
D000970:Antineoplastic Agents; D001215:Asparaginase